Clinical trial
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and…
NCT00362570 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00362570 |
|---|---|
| Title | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma |
| Official title | Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Oligoastrocytoma, Mixed, Anaplastic Oligodendroglioma |
| Intervention type | Drug |
| Interventions | Temozolomide |
| Enrollment | 1 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Mar 1, 2011 |
| First posted | Aug 10, 2006 |
| Last update posted | Nov 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: